The Economics of Cancer Care

Bosanquet, Nicholas; Sikora, Karol

doi:10.1017/cbo9780511545825

Cited by 19 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For years, oncologists have aimed to individualize cancer therapy and to find patient specific chemotherapy treatments that are highly effective or exclude non potent cytostatic drugs [1]. Even if such personalized medication can bring high benefits to cancer patients, so-called chemosensitivity assays are not often performed in cancer treatment [2]. Currently there are a lot of well documented assays on the market, but due to high labor costs of performing those assays, none are part of clinical routine.…”

Section: Personalization Is a Key Topic In Tumor Analysis And Therapymentioning

confidence: 99%

Diagnostic Platform for Personalized Chemosensitivity Assays - Robust Results via Process Automation

Reis

Steiner²,

Siegert

et al. 2012

Biomedical Engineering / Biomedizinische Technik

View full text Add to dashboard Cite

Individualized cancer therapy, as part of personalized medicine, aims for an optimal treatment with minimal side effects. In chemotherapy, one approach is to screen for the most potent combination of chemotherapeutics (chemotherapeutic scheme) to improve quality of life and achieve a high therapy efficacy. Due to high personnel costs associated with the first generation of manual chemosensitivity assays most health insurance providers do not cover this type of therapy. Also, the outcome of such personalized assays has to be proven first. The fully automated DiagnoSYS platform technology is a system effectively using the potential of chemosensitivity assays. It was shown that with an adequate degree of automation, higher reproducibility was achieved. An ATP/TCA assay was used as the first demonstrator assay. Integrated tissue preparation, based on precise regulation of a Miltenyi Biotec M-or C-Tube, combined with magnetic cell enrichment and depletion via EpCAM and CD90 labeling and luminescence based cell vitality measurements, made it possible to enhance the signal to noise ratio of luminescence readings. The platform technology is based on the internationally accepted SBS-format. Therefore, all processing steps, from tissue preparation to luminescence or fluorescence readings, could rapidly and easily be exchanged, and allows for processing different assay approaches, such as ATP/TCA or prognostic biomarkers as uPA/PAI-1, on the same platform. As a result of modular programming, further processing steps could also be implemented without difficulty. Besides the optimization and standardization of personalized assays, cost reduction, which goes hand in hand with automation, will make the platform affordable for research groups and clinical personnel, amplifying the acceptance of personalized medicine approaches in the future.

show abstract

Section: Personalization Is a Key Topic In Tumor Analysis And Therapymentioning

confidence: 99%

Diagnostic Platform for Personalized Chemosensitivity Assays - Robust Results via Process Automation

Reis

Steiner²,

Siegert

et al. 2012

Biomedical Engineering / Biomedizinische Technik

View full text Add to dashboard Cite

show abstract

“…At present, 60% of the world's cancer drugs are sold in the United States, home to less than 5% of our population. 7 But all healthcare systems are struggling to keep up with the burden of ageing populations, novel technology and a much better informed and demanding public.…”

Section: The Current Situationmentioning

confidence: 99%

Cancer care urgently needs a real reform engine

Bosanquet

Sikora²

2009

J R Soc Med

Self Cite

View full text Add to dashboard Cite

“…The problems in cancer therapy to be expected in the future are discussed in detail in a recently published survey [52] . According to this, a flood of new anticancer drugs must be expected in the next few years.…”

Section: Future Prospects For Resistance Assaysmentioning

confidence: 99%

“…Of interest is the conclusion that pharmaceutical firms will not necessarily make a contribution to the development of such technologies, as this would fragment the market for cytostatics. A personalized cancer therapy must also render it possible to include tumor cases that would be better off without drug cancer therapy [52] .…”

Section: Future Prospects For Resistance Assaysmentioning

confidence: 99%

Resistance in Malignant Tumors: Can Resistance Assays Optimize Cytostatic Chemotherapy?

2008

View full text Add to dashboard Cite

The frequent resistance of malignant tumors to chemotherapy documents the fact that numerous patients are uselessly traumatized by highly toxic drugs. Investigations into this resistance have shown that many different mechanisms exist which can abolish the antitumor action of chemotherapeutics. So far, no safe method has been found to counteract this resistance. To date, the only way to avoid harm by an ineffective chemotherapeutic is to refrain from its use when resistance to it is detected. The present survey reports on the available assays that diagnose resistance reliably; sensitivity tests are excluded as being unreliable. Resistance assays are still not fully recognized in hospitals, despite the fact that they are able to optimize chemotherapy by eliminating treatment that is ineffective and merely harmful. Since the number of chemotherapeutics will increase enormously in the future, pharmacological cancer treatment cannot dispense with resistance assays.

show abstract

The Economics of Cancer Care

Cited by 19 publications

References 0 publications

Diagnostic Platform for Personalized Chemosensitivity Assays - Robust Results via Process Automation

Diagnostic Platform for Personalized Chemosensitivity Assays - Robust Results via Process Automation

Cancer care urgently needs a real reform engine

Resistance in Malignant Tumors: Can Resistance Assays Optimize Cytostatic Chemotherapy?

Contact Info

Product

Resources

About